Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Large Cap Fund median (35 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 03 Jan 2013 – 20 Aug 2026. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one. Nifty 100 history starts 25 Jul 2016, so that benchmark is not plotted over this window — pick a shorter range to see it.
View as table
| Date | Taurus Large Cap Fund |
|---|---|
| 03 Jan 2013 | ₹100.00 |
| 22 Feb 2014 | ₹93.09 |
| 13 Apr 2015 | ₹147.34 |
| 31 May 2016 | ₹137.17 |
| 20 Jul 2017 | ₹166.96 |
| 08 Sep 2018 | ₹180.06 |
| 28 Oct 2019 | ₹175.10 |
| 15 Dec 2020 | ₹194.50 |
| 03 Feb 2022 | ₹242.94 |
| 25 Mar 2023 | ₹228.03 |
| 13 May 2024 | ₹336.14 |
| 01 Jul 2025 | ₹375.19 |
| 20 Aug 2026 | ₹394.17 |
| Metric | Taurus · Direct NAV ₹176.35 Very High risk ★★☆☆☆ | Category median Large Cap Fund · 35 funds |
|---|---|---|
| +6.32% | +0.75% | |
| +14.17% | +12.33% | |
| +11.39% | +11.21% | |
| +10.12% | +12.51% | |
| +10.59% | +13.22% | |
| +11.40% | — | |
| +11.30% | +14.61% | |
| +10.70% | +13.78% | |
| +10.93% | +13.95% | |
| Risk | ||
| 13.81% | 13.24% | |
| 0.56 | 0.43 | |
| 0.76 | 0.58 | |
| -35.12% | -35.14% | |
| Nifty 100 | — | |
| +3.96% | +2.33% | |
| 0.98 | 0.96 | |
| 114.8% | 103.3% | |
| 97.6% | 91.0% | |
| 2.54% | 1.07% | |
| ₹49.42Cr | ₹2,004Cr | |
| 1.00% | — | |
| None | — | |
| ₹500 | — | |
| ₹500 | — | |
| 91% | 50% | |
| Anuj Kapil · 3.2y | — | |
| 03 Jan 2013 | — | |
| 35 | — | |
| 53.3% | — | |
| 3.9% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.